Kintor Pharmaceutical Ltd(HK:9939)
HK$1.39+0.01 (+1.09%)
HK:9939
Kintor Pharmaceutical Ltd financials statements
HK$1.39
At close:+0.01 (+1.09%)
Want to see HK:9939 full AI Analyst Report?
Kintor Pharmaceutical Ltd (9939) Ratios
3 Followers
Kintor Pharmaceutical Ltd Ratios
HK:9939's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, HK:9939's free cash flow was increased by ¥49.99M and operating cash flow was ¥-49.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.43 | 1.03 | 2.10 | 4.74 | 6.94 |
| Quick Ratio | 0.34 | 1.02 | 2.10 | 2.84 | 5.35 |
| Cash Ratio | 0.27 | 0.88 | 1.98 | 2.72 | 4.23 |
| Solvency Ratio | -1.05 | -0.62 | -2.55 | -1.68 | -2.01 |
| Operating Cash Flow Ratio | -1.30 | -1.19 | -1.72 | -0.00 | -0.00 |
| Short-Term Operating Cash Flow Coverage | -1.95 | -1.78 | -3.41 | -0.01 | -0.14 |
| Net Current Asset Value | ¥ -103.01M | ¥ -49.32M | ¥ 61.44M | ¥ 947.92M | ¥ 1.11B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.26 | 0.29 | 0.14 | 0.08 |
| Debt-to-Equity Ratio | 0.47 | 0.45 | 0.55 | 0.19 | 0.10 |
| Debt-to-Capital Ratio | 0.32 | 0.31 | 0.36 | 0.16 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.06 | 0.23 | 0.11 | 0.08 |
| Financial Leverage Ratio | 1.87 | 1.75 | 1.90 | 1.37 | 1.25 |
| Debt Service Coverage Ratio | -1.60 | -1.06 | -8.49 | -8.94 | -83.80 |
| Interest Coverage Ratio | -52.00 | -15.58 | -109.31 | -115.37 | -336.65 |
| Debt to Market Cap | 0.11 | 0.34 | 0.39 | 0.08 | 0.04 |
| Interest Debt Per Share | 0.20 | 0.33 | 0.61 | 0.78 | 0.46 |
| Net Debt to EBITDA | -0.37 | 0.11 | 0.18 | 0.61 | 0.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 24.60% | -94.60% | 0.00% | 0.00% | 100.00% |
| EBIT Margin | -527.63% | -2919.94% | 0.00% | 0.00% | -2452.75% |
| EBITDA Margin | -426.01% | -2567.40% | 0.00% | 0.00% | -2422.05% |
| Operating Profit Margin | -611.29% | -2891.36% | 0.00% | 0.00% | -2452.75% |
| Pretax Profit Margin | -621.01% | -3105.48% | 0.00% | 0.00% | -2460.04% |
| Net Profit Margin | -612.29% | -3105.84% | 0.00% | 0.00% | -2460.04% |
| Continuous Operations Profit Margin | -612.29% | -3105.84% | 0.00% | 0.00% | -2460.04% |
| Net Income Per EBT | 98.59% | 100.01% | 99.25% | 100.11% | 100.00% |
| EBT Per EBIT | 101.59% | 107.41% | 100.91% | 100.93% | 100.30% |
| Return on Assets (ROA) | -58.69% | -30.15% | -122.04% | -46.44% | -40.72% |
| Return on Equity (ROE) | -109.54% | -52.81% | -231.56% | -63.83% | -50.88% |
| Return on Capital Employed (ROCE) | -93.65% | -41.49% | -164.35% | -54.38% | -45.43% |
| Return on Invested Capital (ROIC) | -66.83% | -31.33% | -137.83% | -51.32% | -45.20% |
| Return on Tangible Assets | -85.64% | -42.41% | -147.28% | -53.42% | -41.19% |
| Earnings Yield | -25.27% | -39.57% | -166.38% | -29.14% | -23.59% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.32 | 0.30 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.77 | 0.25 | 0.99 | 0.27 | 0.00 |
| Inventory Turnover | 2.04 | 4.39 | 0.00 | 0.04 | 0.00 |
| Fixed Asset Turnover | 0.21 | 0.03 | 0.00 | 0.00 | 1.31 |
| Asset Turnover | 0.10 | 0.01 | 0.00 | 0.00 | 0.02 |
| Working Capital Turnover Ratio | -0.97 | 0.04 | 0.00 | 0.00 | 0.03 |
| Cash Conversion Cycle | -252.93 | -178.40 | -368.54 | 8962.41 | 1124038.43 |
| Days of Sales Outstanding | 43.89 | 1215.50 | 0.00 | 0.00 | 1124038.43 |
| Days of Inventory Outstanding | 179.18 | 83.09 | 0.00 | 10301.57 | 0.00 |
| Days of Payables Outstanding | 475.99 | 1476.99 | 368.54 | 1339.16 | 0.00 |
| Operating Cycle | 223.06 | 1298.59 | 0.00 | 10301.57 | 1124038.43 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.37 | -0.46 | -0.90 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.37 | -0.47 | -0.91 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -228.76 | -118.50 | -142.34 | -34.99 | -13.79 |
| Capital Expenditure Coverage Ratio | -228.76 | -118.50 | -142.34 | -34.99 | -13.79 |
| Operating Cash Flow Coverage Ratio | -1.91 | -1.50 | -1.53 | -0.00 | -0.01 |
| Operating Cash Flow to Sales Ratio | -5.06 | -39.82 | 0.00 | 0.00 | -0.03 |
| Free Cash Flow Yield | -20.97% | -51.16% | -61.21% | -0.03% | -0.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.00 | -2.53 | -0.60 | -3.43 | -4.24 |
| Price-to-Sales (P/S) Ratio | 24.23 | 78.48 | 0.00 | 0.00 | 104.29 |
| Price-to-Book (P/B) Ratio | 4.33 | 1.33 | 1.39 | 2.19 | 2.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.77 | -1.95 | -1.63 | -3312.53 | -3166.04 |
| Price-to-Operating Cash Flow Ratio | -4.79 | -1.97 | -1.65 | -3407.20 | -3395.62 |
| Price-to-Earnings Growth (PEG) Ratio | -0.18 | 0.03 | 0.25 | -0.48 | -0.10 |
| Enterprise Value Multiple | -6.06 | -2.94 | -0.42 | -2.82 | -3.38 |
| Enterprise Value | 843.67M | 377.99M | 446.02M | 2.70B | 2.80B |
| EV to EBITDA | -6.06 | -2.94 | -0.42 | -2.82 | -3.38 |
| EV to Sales | 25.81 | 75.60 | 0.00 | 0.00 | 81.79 |
| EV to Free Cash Flow | -5.08 | -1.88 | -1.14 | -2727.24 | -2482.81 |
| EV to Operating Cash Flow | -5.10 | -1.90 | -1.15 | -2805.18 | -2662.84 |
| Tangible Book Value Per Share | 0.17 | 0.34 | 0.72 | 3.26 | 4.58 |
| Shareholders’ Equity Per Share | 0.41 | 0.68 | 1.07 | 3.97 | 4.64 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | 0.01 | -0.00 | 0.00 |
| Revenue Per Share | 0.07 | 0.01 | 0.00 | 0.00 | 0.10 |
| Net Income Per Share | -0.44 | -0.36 | -2.47 | -2.53 | -2.36 |
| Tax Burden | 0.99 | 1.00 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 1.18 | 1.06 | 1.00 | 0.98 | 1.00 |
| Research & Development to Revenue | 2.67 | 15.63 | 0.00 | 0.00 | 0.02 |
| SG&A to Revenue | 1.83 | 17.68 | 0.00 | 0.00 | 1.31 |
| Stock-Based Compensation to Revenue | 0.00 | -1.85 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 1.28 | 0.36 | 1.01 | 2.04 |
Currency in CNY

